“…Previous studies have shown that Axl is a candidate entry receptor for ZIKV in specific human cell lines—radial glial cells, skin cells, Sertoli cells, fetal and adult endothelial cells, astrocytes, microglia, glioblastoma cells and neural stem cells (based on expression analysis) [ 33 , 34 , 35 , 36 , 55 , 57 , 75 , 90 ]. However, Axl knockdown or knockout failed to show an effect on ZIKV infection in neural progenitor cells in cerebral organoids, TAM knockout mice, and primary genital epithelial cells [ 37 , 91 , 92 ]. Hastings et al (2017) speculated that it is possible that human cell lines may not express the full spectrum of ZIKV receptors present in human cells in vivo [ 38 ], and thus, it is of significant interest to find new or modify existing in vivo models to better mimic the human in vivo system.…”